Skip to main content
Equibles
SGHT logo

SGHT · Sight Sciences, Inc.

Track SGHT — free

Use SGHT with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research SGHT.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$8.14 +0.14 (+1.69%) At close · Sep 11
Russell 2000 member Rebalance outlook locked
Market Cap
$448.42M
Shares
55.09M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$8.14 Open$8.13 Day$7.99–8.32 52W close$3.20–9.05 Avg vol 30d268K Short int1.2M · 2.2% float · 5.5d Short vol56% Last earningsAug 5, 2026 DataJul 2021–Sep 2026 Filing10-Q · Aug 5

Up next

Next earnings call
Nov 4, 2026 Est · unconfirmed · in 8 wks
Latest filing: 10-Q
filed Aug 5, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$83.38M
Trailing 12 months
Net income (TTM)
−$29.76M
Trailing 12 months
Revenue growth YoY
+19.5%
Year over year
Operating margin
-33.4%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$38.98M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+5.2%
Year over year · more shares
Price change (1Y)
+134.8%
Trailing year
Short interest
2.2%
Latest settlement · 5.5 days to cover
View all 115 metrics

AI Brief

Q2 FY26 earnings call · Aug 5, 2026
Q2 FY26

TL;DR. Sight Sciences posted 20% Q2 revenue growth, raised full-year 2026 revenue guidance to $88–$92M and lowered adjusted operating expense guidance to $92–$94M, driven by record Interventional Dry Eye sales and a fourth consecutive quarter of Interventional Glaucoma growth.

Bullish
  • + Total Q2 revenue grew 20% year-over-year to $23.4M, the strongest growth rate in three years
  • + Interventional Dry Eye achieved record revenue of $2.7M, nearly doubling sequentially and up 704% year-over-year
  • + Raised full-year 2026 revenue guidance to $88–$92M, including raising IDE guidance to $9–$11M from $6–$8M
  • + Interventional Glaucoma posted its fourth consecutive quarter of YoY growth at $20.7M, up 8%, with a record number of active accounts
  • + Reduced full-year 2026 adjusted operating expense guidance to $92–$94M from $93–$96M while net loss improved 63%
  • + IDE covered lives increased to ~14.5M from ~10.4M and Aetna added ~25M covered lives for IG, completing coverage across all major national payers
Bearish
  • − Q3 2026 IG revenue is expected to grow only in the mid-single digits against a tougher prior-year comparison and historical seasonality

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Buy Momentum Strong Sentiment Neutral Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 15.8 · calm Equity put/call 0.60
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +39%
above
Price vs 50-day avg +20%
above
RSI (14) 59
neutral
MACD trend Negative
52-week position 84%
mid-range
Momentum
relative strength
Strong
1-month return −2%
trailing
6-month return +135%
trailing
YTD return +3%
this year
Relative strength +117%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $7 › 200d $6 — 50d above 200d
Institutional flow Distributing
-3% holders QoQ · +15 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
2.22% of float · ▲ +38.5% MoM · 5.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
111 holders — near 3-yr high, broad support
Squeeze score 67
elevated · 0–100
Fundamentals
Strong
Revenue growth −3%
Y/Y
Gross margin 86%
expanding
EPS growth +28%
Y/Y
Free cash flow $-29.9M
Balance sheet $51.7M
net cash
Quant / Vol
risk profile
Very High
Volatility 84%
annualized · 1-yr
Max drawdown −62%
past year
ATR 4.9%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the 8-K filed Aug 5, 2026
Interventional Glaucoma revenue · full year 2026 Initiated $79M – $81M
Prior guidance period ended · from the 8-K filed Aug 1, 2024
Adjusted operating expenses · full year 2024 $107M – $109M
Guided vs delivered · last 1 settled
Full-year 2021 revenue full-year 2021
guided $46M – $48M
$48.96M Beat +4.2%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy
1 · 3 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+39% Bullish
Price vs 50-day avg
+20% Bullish
RSI (14)
59 Neutral
MACD trend
Negative Bearish
52-week position
84% Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $7 › 200d $6 — 50d above 200d
Institutional flow Distributing
-3% holders QoQ · +15 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
2.22% of float · ▲ +38.5% MoM · 5.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
111 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $3 Now $8 · 84% Range high $9
vs 200-day avg +39% vs 50-day avg +20%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Medical Devices — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
SGHT
Sight Sciences, Inc.
this stock
$448.42M +2.6% -3.1% — 2.2%
ABT
Abbott Laboratories
 $177.58B -18.6% +5.7% 28.6 1.3%
MDT
Medtronic plc
 $116.35B -5.3% +8.4% 22.4 0.9%
SYK
Stryker Corp
 $105.70B -21.6% +11.2% 28.6 2.0%
BSX
Boston Scientific Corp
 $62.29B -54.9% +12.5% 17.4 3.3%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
111
% held
40.2%
Net QoQ
-398.8K sh
Top holder
Long Focus Capital Manage…
Held Float
View
Held by Funds
Fund positions
115
View
Short & Settlement
Short Interest Rising
Shares short
1.2M
Days to cover
5.5d
Change
+339.9K sh
View
Short Volume
Short vol %
56%
As of
Sep 11, 2026
Short Total
View
Fails to Deliver
FTD shares
5.2K
Value
$29.4K
As of
Aug 5, 2026
View
Off-Exchange
Off-exchange %
43.8%
Week of
Aug 3, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$77.4M
Net income (FY)
$-38.4M
EPS diluted
$-0.74
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 10, 2026
This year
13
View
Proposed Sales
Value
$101.3K
Shares
12.2K
Filed
Sep 4, 2026
View
Exempt Offerings
Offering
$23.2M
Filed
Dec 10, 2020
View
Earnings & Events
Earnings Calls
Last call
Aug 5, 2026
View
Investor Relations
Latest news
Sight Sciences to Present at the…
Published
Sep 1, 2026
View

Performance

5D 20D 120D MTD YTD
SGHT -2.9% -2.2% +134.6% -4.2% +2.7%
SPY -1.2% -1.8% +17.8% -0.4% +12.1%
vs SPY -1.7% -0.4% +116.7% -3.9% -9.4%
Key facts CIK 1531177 CUSIP 82657M105 13F (30d) 60 filings 60 filers Visit website Investor relations